← Back to Search

Anticholinergic

Low Dose (2 mg) for Excessive Sweating

Phase 2
Waitlist Available
Research Sponsored by Atacama Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline (day 1) to end of study (day 43)
Awards & highlights

Study Summary

This is a multicenter, randomized, double-blind, placebo-controlled, parallel group comparison study of AT-5214 in subjects with moderate to severe primary palmar hyperhidrosis (sweaty palms). This study will compare two different oral (tablet) doses of AT-5214 (study drug) versus a matched placebo. Approximately 120 subjects will be enrolled at approximately 10 study sites.

Eligible Conditions
  • Excessive Sweating
  • Excessive Hand Sweating

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline (day 1) to end of study (day 43)
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline (day 1) to end of study (day 43) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
PHIS Reduction
Secondary outcome measures
Absolute change in PHIS
Absolute change of Sweat Production
Change in Sweat Production
Other outcome measures
Number of Subjects with Adverse Events (AEs)

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: Low Dose (2 mg)Experimental Treatment1 Intervention
Oral tablet containing 1 mg of active drug, dexmecamylamine HCl. Subjects will be instructed to take two tablets by mouth twice daily (in the morning and evening).
Group II: High Dose (4 mg)Experimental Treatment1 Intervention
Oral tablet containing 2 mg of active drug, dexmecamylamine HCl. Subjects will be instructed to take two tablets by mouth twice daily (in the morning and evening).
Group III: PlaceboPlacebo Group1 Intervention
Oral tablet containing no active drug. Subjects will be instructed to take two tablets by mouth twice daily (in the morning and evening).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dexmecamylamine
Not yet FDA approved

Find a Location

Who is running the clinical trial?

Atacama TherapeuticsLead Sponsor
1 Previous Clinical Trials
60 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Clinical Study to Assess the Efficacy and Safety of AT-5214 in the Treatment of Subjects With Palmar Hyperhidrosis
2020. "Clinical Study to Assess the Efficacy and Safety of AT-5214 in the Treatment of Subjects With Palmar Hyperhidrosis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04263623.
All > Hyperhidrosis
~15 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top